Go Pro
NYSEAMERICAN:CCEL

Cryo-Cell International (CCEL) Stock Price, News & Analysis

Cryo-Cell International logo
$3.36 -0.01 (-0.30%)
Closing price 04:10 PM Eastern
Extended Trading
$3.36 +0.01 (+0.15%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Cryo-Cell International Stock (NYSEAMERICAN:CCEL)

Advanced

Key Stats

Today's Range
$3.35
$3.70
50-Day Range
$2.90
$4.05
52-Week Range
$2.72
$5.43
Volume
20,681 shs
Average Volume
12,258 shs
Market Capitalization
$27.08 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Hold

Company Overview

Cryo-Cell International, Inc. is a pioneering provider of umbilical cord blood and tissue preservation services. Headquartered in Oldsmar, Florida, the company was founded in 1989 as the first private cord blood bank in the United States. Cryo-Cell operates FDA-registered and AABB-accredited laboratory facilities, maintaining stringent quality control measures and cryogenic storage systems to safeguard stem cell viability over long-term storage periods.

The company’s primary business activity centers on the collection, processing and secure storage of newborn stem cell sources harvested at birth. Trained medical personnel coordinate with healthcare providers to collect cord blood and cord tissue immediately after delivery. Samples are shipped in temperature-controlled containers to Cryo-Cell’s processing laboratories, where stem cell fractions are isolated, tested for purity and viability, and ultimately cryogenically stored in liquid nitrogen tanks.

Cryo-Cell serves families across the United States and in select international markets through a network of distribution partners. In addition to its core storage offerings, the company provides customized preservation plans, educational materials and dedicated client support to prospective parents. Cryo-Cell also collaborates with research institutions and participates in industry initiatives aimed at expanding the therapeutic applications of cord blood and tissue derivatives.

Guided by an experienced management team with expertise in biotechnology, clinical operations and regulatory affairs, Cryo-Cell International continues to invest in advanced processing technologies and service expansion. The company’s focus on safety, compliance and customer engagement positions it as a leading player in the evolving field of regenerative medicine and stem cell banking.

AI Generated. May Contain Errors.

Cryo-Cell International Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
6th Percentile Overall Score

CCEL MarketRank™: 

Cryo-Cell International scored higher than 6% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Cryo-Cell International has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, no buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Cryo-Cell International has received no research coverage in the past 90 days.

  • Read more about Cryo-Cell International's stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Cryo-Cell International is -11.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Cryo-Cell International is -11.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Percentage of Shares Shorted

    0.19% of the float of Cryo-Cell International has been sold short.
  • Short Interest Ratio / Days to Cover

    Cryo-Cell International has a short interest ratio ("days to cover") of 0.65, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Cryo-Cell International has recently increased by 45.15%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Cryo-Cell International does not currently pay a dividend.

  • Dividend Growth

    Cryo-Cell International does not have a long track record of dividend growth.

    • Insider Buying vs. Insider Selling

      In the past three months, Cryo-Cell International insiders have not sold or bought any company stock.

    • Percentage Held by Insiders

      38.59% of the stock of Cryo-Cell International is held by insiders. A high percentage of insider ownership can be a sign of company health.

    • Percentage Held by Institutions

      10.44% of the stock of Cryo-Cell International is held by institutions.

    • Read more about Cryo-Cell International's insider trading history.
    Receive CCEL Stock News and Ratings via Email

    Sign-up to receive the latest news and ratings for Cryo-Cell International and its competitors with MarketBeat's FREE daily newsletter.

    SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

    CCEL Stock News Headlines

    Elon says "don't save money." Is he right?
    Elon Musk says there will be no poverty in the future and that money won't matter in ten years. Until that day arrives, one existing program already pays out on a similar promise. The Patriot Income Plan issues 42 payouts a year - roughly once a week - funded by partnerships that control America's critical infrastructure, not tax dollars. Enrollees have historically received a 10 percent annual yield, and since 2020 the average partnership has produced 20 percent average annual gains.tc pixel
    Wall Street Analysts Are Neutral on Top Healthcare Picks
    See More Headlines

    CCEL Stock Analysis - Frequently Asked Questions

    Cryo-Cell International's stock was trading at $3.44 on January 1st, 2026. Since then, CCEL shares have decreased by 2.3% and is now trading at $3.36.

    Cryo-Cell International Inc. (NYSEAMERICAN:CCEL) released its quarterly earnings data on Wednesday, July, 15th. The company reported $0.07 EPS for the quarter. The firm earned $7.78 million during the quarter.

    Shares of CCEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

    Based on aggregate information from My MarketBeat watchlists, some other companies that Cryo-Cell International investors own include Meta Platforms (META), Alimera Sciences (ALIM), Crescent Biopharma (CBIO), NVIDIA (NVDA), Aspen Group (ASPU).

    Company Calendar

    Last Earnings
    7/15/2026
    Today
    7/30/2026
    Fiscal Year End
    11/30/2026

    Industry, Sector and Symbol

    Stock Exchange
    NYSEAMERICAN
    Sector
    Medical
    Industry
    Medical Services
    Sub-Industry
    Healthcare
    Current Symbol
    NYSEAMERICAN:CCEL
    CIK
    862692
    Employees
    90
    Year Founded
    1989

    Profitability

    EPS (Trailing Twelve Months)
    ($1.06)
    Trailing P/E Ratio
    N/A
    Forward P/E Ratio
    N/A
    P/E Growth
    N/A
    Net Income
    -$2.43 million
    Net Margins
    -7.92%
    Pretax Margin
    -8.18%
    Return on Equity
    N/A
    Return on Assets
    -4.00%

    Debt

    Debt-to-Equity Ratio
    N/A
    Current Ratio
    0.71
    Quick Ratio
    0.69

    Sales & Book Value

    Annual Sales
    $31.57 million
    Price / Sales
    0.86
    Cash Flow
    N/A
    Price / Cash Flow
    N/A
    Book Value
    ($2.20) per share
    Price / Book
    -1.53

    Miscellaneous

    Outstanding Shares
    8,060,000
    Free Float
    4,951,000
    Market Cap
    $27.08 million
    Optionable
    Not Optionable
    Beta
    0.49

    Social Links

    10 Stocks Powering The Next AI Boom  Cover

    The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

    Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

    Get This Free Report

    This page (NYSEAMERICAN:CCEL) was last updated on 7/30/2026 by MarketBeat.com Staff.
    From Our Partners